Endometrial Polyp

Comprehensive Clinical Guide: Endometrial Polyps

1. Introduction and Clinical Overview

An endometrial polyp, also clinically referred to as a uterine polyp, is a localized overgrowth of the endometrial glandular and stromal elements that projects into the uterine cavity. These lesions can be sessile (flat-based) or pedunculated (attached by a stalk) and vary significantly in size, ranging from a few millimeters to several centimeters.

Endometrial polyps are among the most common gynecological pathologies, with an estimated prevalence between 10% and 24% in the general female population. While frequently asymptomatic and often discovered incidentally during routine gynecological ultrasound or during the investigation of infertility, they are clinically significant due to their potential to cause abnormal uterine bleeding (AUB) and their association with reproductive morbidity. Although the vast majority of endometrial polyps are benign, a small percentage may harbor premalignant or malignant changes, necessitating a structured approach to diagnosis and clinical management.

2. Etiology and Pathophysiology

The precise molecular mechanisms underlying the development of endometrial polyps remain a subject of extensive research. However, clinical evidence points toward a multifactorial etiology involving hormonal, genetic, and environmental factors.

The Hormonal Influence

Endometrial polyps are estrogen-dependent lesions. They possess a higher density of estrogen receptors (ER) and progesterone receptors (PR) compared to the surrounding endometrium. Furthermore, the expression of aromatase—the enzyme responsible for the conversion of androgens to estrogens—is significantly elevated in the glandular epithelium of the polyps. This localized hyperestrogenic state promotes the focal proliferation of the endometrial lining.

Genetic and Molecular Markers

Current literature suggests that polyps often arise from monoclonal expansions. Several key molecular pathways have been implicated:
* HMGA2 Expression: Overexpression of the High Mobility Group AT-hook 2 (HMGA2) gene is frequently observed in endometrial polyps.
* Chromosomal Aberrations: Recurrent rearrangements in chromosomes 6, 7, and 12 are common in hyperplastic polyps.
* BCL-2 Overexpression: Increased expression of the anti-apoptotic protein BCL-2 contributes to the survival and growth of the polypoid tissue.

Risk Factors

3. Clinical Presentation and Diagnosis

The clinical manifestation of an endometrial polyp is highly variable. Many patients remain asymptomatic. When symptoms do occur, they are typically linked to the mechanical disruption of the endometrial surface or the hormonal activity of the polyp.

Standard Clinical Presentation

• Abnormal Uterine Bleeding (AUB): The most frequent symptom, including intermenstrual bleeding (metrorrhagia), heavy menstrual bleeding (menorrhagia), or postmenopausal bleeding.
• Infertility: Polyps can act as physical barriers to sperm transport or interfere with embryo implantation through the secretion of inflammatory cytokines.
• Pelvic Pain: Less common, but possible if the polyp prolapses through the cervix.

Diagnostic Modalities

The gold standard for diagnosis is the direct visualization of the uterine cavity.

1. Transvaginal Ultrasound (TVS): The primary screening tool. Polyps appear as hyperechoic masses within the endometrial cavity.
2. Saline Infusion Sonohysterography (SIS): Highly sensitive (up to 95%). By distending the uterine cavity with saline, the clinician can clearly distinguish a polyp from focal endometrial hyperplasia or a submucosal fibroid.
3. Hysteroscopy: The definitive diagnostic and therapeutic tool. It allows for direct visualization and targeted biopsy or resection (polypectomy).

4. Differential Diagnosis

Differentiating endometrial polyps from other intrauterine pathologies is critical for effective management.

• Submucosal Leiomyomas (Fibroids): Often firmer and lack the vascular pattern seen in polyps; typically exhibit a broader base.
• Endometrial Hyperplasia: Usually presents as diffuse thickening of the endometrium rather than a focal lesion.
• Endometrial Carcinoma: Must be ruled out in postmenopausal patients with bleeding. Irregular surface, necrosis, and abnormal vascularity are red flags.
• Retained Products of Conception (RPOC): History of recent pregnancy or termination is key; vascularity on Doppler ultrasound is usually more chaotic.

5. Management and Therapeutic Interventions

The decision to treat an endometrial polyp depends on the patient's symptoms, menopausal status, and risk factors for malignancy.

Indications for Polypectomy

• Symptomatic Polyps: Any polyp causing AUB or infertility.
• Postmenopausal Polyps: Due to the higher risk of malignancy, surgical removal is generally recommended regardless of symptoms.
• Large Polyps (>1.5 cm): Higher potential for malignant transformation.
• Endometrial Thickening: When the polyp obscures the endometrial-myometrial junction.

Surgical Technique: Hysteroscopic Polypectomy

Hysteroscopic polypectomy is the preferred surgical approach. It is minimally invasive, performed under anesthesia, and allows for the complete excision of the polyp base, which is crucial for preventing recurrence. The use of a resectoscope or mechanical hysteroscopic morcellators has significantly improved surgical outcomes and reduced operative time.

6. Risks, Side Effects, and Prognosis

While the prognosis for benign endometrial polyps is excellent following resection, patients must be monitored for recurrence.

• Recurrence: Reported in 2.5% to 40% of cases. Risk factors for recurrence include multiple polyps, larger size, and underlying hormonal imbalances.
• Malignancy: The overall risk of malignancy in a polyp is low (approximately 1-3%). However, this risk increases significantly in postmenopausal women with bleeding.
• Post-Surgical Risks: Although rare, complications include uterine perforation, cervical trauma, fluid overload (if using monopolar energy), and infection.

7. Frequently Asked Questions (FAQ)

1. Are endometrial polyps cancerous?
Most endometrial polyps are benign. However, a small percentage can contain malignant cells. Postmenopausal women have a slightly higher risk of malignancy compared to premenopausal women.

2. Can an endometrial polyp prevent me from getting pregnant?
Yes. Polyps can interfere with implantation by altering the local environment of the endometrium or by acting as a physical obstruction to the fallopian tubes or cervical canal.

3. Does a polyp always require surgery?
No. Asymptomatic polyps in premenopausal women that are small in size may be managed with "expectant management" or periodic observation.

4. How is a polyp different from a fibroid?
Polyps are overgrowths of the inner lining (endometrium), while fibroids are growths of the muscular wall of the uterus (myometrium).

5. Will a polyp come back after it is removed?
Recurrence is possible. It is estimated that 2% to 40% of patients may develop a new polyp after initial removal, depending on individual hormonal factors.

6. Does Tamoxifen use increase my risk?
Yes. Tamoxifen, a medication often used for breast cancer, has estrogenic effects on the uterus, which can lead to the formation of endometrial polyps.

7. Is an ultrasound enough to diagnose a polyp?
Ultrasound is an excellent screening tool, but SIS or hysteroscopy is often required for a definitive diagnosis and to differentiate it from other conditions.

8. Is the procedure to remove a polyp painful?
Hysteroscopic polypectomy is performed under sedation or general anesthesia, so there is no pain during the procedure. Mild cramping may occur afterward.

9. Can polyps cause spotting between periods?
Yes, intermenstrual bleeding or "spotting" is one of the most common clinical indicators of an endometrial polyp.

10. What is the role of biopsy?
Pathological examination of the removed tissue is mandatory to confirm the diagnosis and definitively rule out malignancy or atypical hyperplasia.

8. Conclusion and Clinical Outlook

Endometrial polyps remain a core diagnostic challenge in gynecological practice. While generally benign, their impact on quality of life, fertility, and the potential for malignancy requires a nuanced clinical strategy. Advances in hysteroscopic technology have made the management of these lesions safer and more effective. For the clinician, the focus must remain on the accurate identification of high-risk cases and the judicious application of surgical intervention, balanced against the patient's overall reproductive and systemic health. Future research into the molecular pathogenesis of these lesions may eventually lead to non-surgical, medical management options for high-risk patients.